Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 28 citing articles:

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
Karen Van Baelen, Tatjana Geukens, Marion Maetens, et al.
Annals of Oncology (2022) Vol. 33, Iss. 8, pp. 769-785
Open Access | Times Cited: 80
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Aleix Prat, Fara Brasó‐Maristany, Olga Martínez‐Sáez, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 33
Seize the engine: Emerging cell cycle targets in breast cancer
Jesús Fuentes‐Antrás, Philippe L. Bédard, David W. Cescon
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer
Hongnan Mo, Xuefeng Liu, Yu Xue, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 31
How I treat endocrine-dependent metastatic breast cancer
Andrea Gombos, Anthony Gonçalvès, Giuseppe Curigliano, et al.
ESMO Open (2023) Vol. 8, Iss. 2, pp. 100882-100882
Open Access | Times Cited: 17
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Matthew P. Goetz, Erika Hamilton, Mario Campone, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 10, pp. 2233-2244
Open Access | Times Cited: 16
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
Ilenia Migliaccio, Cristina Guarducci, Luca Malorni
Advances in experimental medicine and biology (2025), pp. 475-493
Closed Access
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Farasat Kazmi, Nipun Shrestha, Tiaotiao Liu, et al.
Cochrane library (2025) Vol. 2025, Iss. 3
Open Access
Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR + /HER2- metastatic breast cancer patients
Miriam González-Conde, Celso Yáñez, Carmen Abuín, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
Soo Hyun Lee, Kyunghee Park, Gun Min Kim, et al.
The Breast (2022) Vol. 62, pp. 52-60
Open Access | Times Cited: 18
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis
Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 10
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Stephen Johnston, Anna Emde, Carlos H. Barrios, et al.
JNCI Cancer Spectrum (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 10
The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
Corinna Keup, Rainer Kimmig, Sabine Kasimir‐Bauer
Cancers (2023) Vol. 15, Iss. 22, pp. 5463-5463
Open Access | Times Cited: 10
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project
Masaya Hattori, Victoria Serelli-Lee, Yoichi Naito, et al.
JCO Precision Oncology (2024), Iss. 8
Open Access | Times Cited: 2
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
Eriseld Krasniqi, Frauke Goeman, Claudio Pulito, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14534-14534
Open Access | Times Cited: 12
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis
Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, et al.
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis
Ta‐Chung Chao, Yi‐Fang Tsai, Chun‐Yu Liu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer
Kristina Fanucci, Antonio Giordano, Timothy K. Erick, et al.
ESMO Open (2024) Vol. 9, Iss. 12, pp. 103997-103997
Open Access | Times Cited: 1
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
Sasha Main, David W. Cescon, Scott V. Bratman
Cancer Drug Resistance (2022) Vol. 5, Iss. 3, pp. 727-48
Open Access | Times Cited: 6
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach
Caterina Fontanella, Carlo Alberto Giorgi, Stefania Russo, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 180, pp. 103848-103848
Open Access | Times Cited: 5
Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review
Lu Gao, Xia‐Bo Shen, Libin He, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 2, pp. 117-117
Open Access | Times Cited: 3
Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia
Dora Čerina, Natalija Dedić Plavetić, Ingrid Belac-Lovasić, et al.
The Breast Journal (2024) Vol. 2024, Iss. 1
Open Access
Improving the Outcome of Bad-Acting Hormone Receptor–Positive Breast Cancer
William J. Gradishar
New England Journal of Medicine (2024) Vol. 391, Iss. 17, pp. 1644-1647
Closed Access
Breast Cancer Pathology in the Era of Genomics
Hannah Y. Wen, Laura C. Collins
(2024) Vol. 14, Iss. 1, pp. 15-32
Closed Access
Page 1 - Next Page

Scroll to top